Seer, Inc.
$1.99
0%
2026-04-21 09:21:00
seer.bio
NMS: SEER
Explore Seer, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$112.84 M
Current Price
$1.99
52W High / Low
$2.41 / $1.65
Stock P/E
—
Book Value
$4.61
Dividend Yield
—
ROCE
-27.82%
ROE
-25.08%
Face Value
—
EPS
$-1.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
124
Beta
1.6
Debt / Equity
9.12
Current Ratio
12.84
Quick Ratio
12.35
Forward P/E
-1.61
Price / Sales
5.75
Enterprise Value
$-66.89 M
EV / EBITDA
0.93
EV / Revenue
-4.04
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
| 2. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 3. | Neurogene Inc. | $27.74 | — | $432.03 M | — | -37.96% | -31.41% | $37.27 / $10.46 | $17.1 |
| 4. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 5. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 6. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
| 7. | Nutriband Inc. | $4.2 | — | $51.13 M | — | -103.12% | -1.36% | $11.68 / $3.42 | $0.62 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 4.07 M | 3.97 M | 3.93 M | 4.14 M | 3.95 M | — |
| Operating Profit | -17.39 M | -19.35 M | -20.53 M | -20.73 M | -23.49 M | — |
| Net Profit | -15.99 M | -18.23 M | -19.42 M | -19.95 M | -21.74 M | — |
| EPS in Rs | -0.28 | -0.32 | -0.34 | -0.35 | -0.39 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 16.12 M | 13.95 M | 15.18 M | 14.69 M |
| Operating Profit | -77.99 M | -100.1 M | -103.46 M | -97.23 M |
| Net Profit | -73.6 M | -86.6 M | -86.28 M | -92.97 M |
| EPS in Rs | -1.3 | -1.53 | -1.53 | -1.65 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 296.08 M | 366.6 M | 436.27 M | 487.93 M |
| Total Liabilities | 36.78 M | 39.03 M | 39.37 M | 40.94 M |
| Equity | 259.31 M | 327.57 M | 396.9 M | 446.99 M |
| Current Assets | 201.53 M | 253.32 M | 330.51 M | 434.98 M |
| Current Liabilities | 15.69 M | 15.33 M | 13.22 M | 12.58 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -44.45 M | -46.11 M | -59.06 M | -60.78 M |
| Investing CF | 61.55 M | 65.86 M | 37.9 M | -122.72 M |
| Financing CF | -10.57 M | -11.49 M | 0.45 M | 3.89 M |
| Free CF | -46.24 M | -49.69 M | -66.37 M | -71.05 M |
| Capex | -1.8 M | -3.58 M | -7.31 M | -10.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -8.13% | 3.38% | — | — |
| Earnings Growth % | -0.37% | 7.2% | — | — |
| Profit Margin % | -620.91% | -568.28% | -633.07% | — |
| Operating Margin % | -717.72% | -681.48% | -662.14% | — |
| Gross Margin % | 48.99% | 46.29% | 42.8% | — |
| EBITDA Margin % | -673.44% | -644.74% | -635.29% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.